Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur(Novartis (Switzerland)), Darrin D. Stuart(Scorpion Therapeutics (United States)), Mitchell P. Levesque(University of Zurich), Nancy Pryer(Novartis (United States)), Allison Landman(University of California, San Francisco), William R. Sellers(Broad Institute), Martin McMahon(UCSF Helen Diller Family Comprehensive Cancer Center), Reinhard Dummer(University of Zurich), Fernando Salangsang(Novartis (Switzerland))
Cited by 735
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k